MCL Literature Feed

A rare case of composite MCL and lymphoplasmacytic lymphoma in bone marrow highlights the necessity of advanced diagnostics like NGS and FISH to differentiate from MCL with plasmacytic differentiation.

The polatuzumab-based regimen, Pola-R-mini-CHP, demonstrated efficacy in elderly relapsed/refractory MCL, offering a potential new ADC-chemoimmunotherapy option for this difficult-to-treat population.

This first case report of concurrent zanubrutinib and radiotherapy demonstrates a manageable safety profile, suggesting BTKi therapy may not require interruption for necessary radiation in MCL patients.

Bendamustine-induced lymphopenia in frontline MCL resolves by 12 months, suggesting a minimum 9-month wait before leukapheresis for CAR-T therapy to ensure sufficient lymphocyte collection.

A rare case of primary bone MCL presenting as a psoas abscess with multiple vertebral lesions highlights a diagnostic pitfall where extranodal lymphoma can mimic musculoskeletal infection.

Real-world US Medicare data shows elderly MCL patients post-cBTKi have a dismal median OS of 9.4 months and high costs, highlighting the urgent need for effective therapies.

This case of cardiac MCL with a mobile tumor highlights the risk of fatal pulmonary embolism post-chemotherapy, suggesting a potential role for pre-treatment surgical intervention in this rare presentation.

In older, frontline MCL patients, adding bortezomib to BR induction or lenalidomide to rituximab maintenance did not improve PFS, confirming BR-R as a highly effective standard.

Hyperleukocytosis from undiagnosed leukemic MCL interfered with an HbA1c test, revealing a novel diagnostic pathway where a common diabetes lab test can signal an underlying hematologic malignancy.

A rare case of mantle cell lymphoma discovered incidentally within a benign Warthin tumor highlights a diagnostic pitfall, underscoring the need to pathologically evaluate lymphoid stroma to avoid missed diagnoses.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

This case report details an extremely rare presentation of relapsed mantle cell lymphoma as an appendiceal volvulus, highlighting an unusual cause of acute abdominal pain requiring emergent surgery.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This case report of an 80-year-old woman with laryngeal MCL highlights a rare extranodal presentation, underscoring the need to consider lymphoma in the differential for persistent throat symptoms.

An 85-year-old MCL patient on ibrutinib developed a cutaneous EBV+ NK/T-cell lymphoma that resolved spontaneously, highlighting a rare, potentially indolent lymphoproliferative disorder in this treatment setting.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

This case report describes a rare presentation of primary, localized orbital mantle cell lymphoma successfully managed with local excision and radiotherapy, highlighting an unusual clinical scenario for this systemic disease.

This case report highlights unprovoked venous thromboembolism as a presenting symptom of mantle cell lymphoma, underscoring the need for a prompt malignancy workup in such clinical scenarios.

Real-world UK data show first-line ibrutinib is effective and tolerable for older MCL patients, but high-risk subgroups (TP53-mutated, blastoid) have significantly inferior survival, highlighting an unmet need.

Large B-cell lymphoma with IRF4 rearrangement can mimic blastoid MCL by presenting in older adults and expressing CD5, but negativity for Cyclin D1 and SOX11 is crucial for differential diagnosis.

Palliative radiotherapy provided profound tumor reduction for an elderly patient with blastoid MCL presenting as a rare oropharyngeal mass, demonstrating a personalized, less-intensive frontline treatment option.

This case report describes an extremely rare pancreatic collision tumor of MCL and adenocarcinoma, hypothesizing a potential role for cyclin D1 in promoting the second malignancy.

In elderly MCL, rituximab maintenance benefits even MRD-negative patients post-induction, arguing against de-escalation and identifying MRD-positivity as a high-risk feature needing better consolidation.

This retrospective study found 36% of ibrutinib-treated patients, including MCL, developed serious infections, with prior transplant and steroid use identifying a high-risk group needing potential prophylaxis.

This real-world study shows significant MCL-related mortality after first relapse (23%), suggesting high-risk patients may not survive to receive novel therapies, supporting their use in earlier lines.

This Japanese post-marketing surveillance study confirms the real-world efficacy (59.9% ORR) and safety of ibrutinib in heavily pre-treated, elderly patients with relapsed/refractory MCL, supporting its routine use.

This review summarizes the evolution of MCL treatment, focusing on BTK inhibitor efficacy, toxicity, and their role in enabling personalized therapeutic strategies based on patient and disease factors.

The British Society for Haematology provides updated, evidence-based guidelines on MCL diagnosis, risk stratification, and treatment algorithms, standardizing care for UK patients.